ClinicalTrials.gg
CompletedNCT02545504GAMMA-1Updated May 26, 2020Results posted

Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

A Phase 3 interventional study of Andecaliximab and Placebo in Gastric Adenocarcinoma, sponsored by Gilead Sciences. Completed at 134 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-05-26.

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
432
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 804 studies in Stomach Neoplasms with a site in United States — 157 open to participants now, 239 under way, 12 of them phase 3. Stomach Neoplasms · United States.

Enrollment
57th of 686
432 · median 53
Started
2015
with 23 others
Phase 3
39 of 804
6 open now
Registered
330th of 804
by date

Among the 804 studies in Stomach Neoplasms with a site in United States, this one is the 57th largest by enrollment of the 686 interventional ones that give a count, is one of 24 that started in 2015, is one of 39 in phase 3, and was the 330th registered.

Stomach Neoplasms

3,403 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

157 of the 804 studies in Stomach Neoplasms with a site in United States are open now. Recruiting first, the newest first:

152 more — sign in →

All 157 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 804 studies in Stomach Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this study is to compare the efficacy of andecaliximab (GS-5745) versus placebo in combination with modified fluorouracil (5-FU), leucovorin (LV), and oxaliplatin (OXA) (mFOLFOX6) as measured by overall survival.

03

Conditions studied

  • Gastric Adenocarcinoma

Browse trials for

Keywords

  • Gastroesophageal junction (GEJ)
  • Stomach cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Adults with confirmed adenocarcinoma of the stomach or gastroesophageal junction that is inoperable, locally advanced or and not amenable to curative therapy
  • Adequate hematologic, liver, coagulation and kidney function
  • (ECOG) ≤ 1
  • Evaluable disease per (RECIST) v 1.1

Key Exclusion Criteria:

  • Previous chemotherapy for locally advanced or metastatic gastric cancer.
  • Human Epidermal Growth Factor Receptor 2 ()-positive gastric cancer
  • , virus (HBV), or virus (HCV) infection
  • Pregnant or breast feeding women
  • Individuals with known or suspected central nervous system metastases or individuals requiring chronic daily treatment with oral
  • Grade ≥ 2 peripheral neuropathy

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
432 participants (actual)

Study arms

  • Experimental
    Andecaliximab

    Andecaliximab plus mFOLFOX6 (LV+5-FU+OXA) during Cycles 1-6, followed by andecaliximab plus LV+5-FU during subsequent cycles

    Drug: Andecaliximab · Drug: Leucovorin · Drug: 5-fluorouracil · Drug: Oxaliplatin

  • Placebo comparator
    Placebo

    Placebo plus mFOLFOX6 (LV+5-FU+OXA) during Cycles 1-6, followed by placebo plus LV+5-FU during subsequent cycles

    Drug: Placebo · Drug: Leucovorin · Drug: 5-fluorouracil · Drug: Oxaliplatin

Interventions

  • 800 mg administered intravenously on Days 1 and 15 of each 28-day treatment cycle

    Also known as: GS-5745

  • DrugPlacebo

    Administered intravenously on Days 1 and 15 of each treatment cycle

  • Administered intravenously per standard of care on Days 1 and 15 of each treatment cycle

    Also known as: LV

  • Administered intravenously per standard of care on Days 1 and 15 of each treatment cycle

    Also known as: 5-FU

  • Administered intravenously per standard of care on Days 1 and 15 of each treatment cycle

    Also known as: OXA

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    OS was defined as the time interval from the date of randomization to death from any cause.

    Time frame: Andecaliximab + mFOLFOX6 median follow-up at the time of final analysis: 19.43 months; Placebo + mFOLFOX6 median follow-up at the time of the final analysis: 19.45 months

Secondary outcomes

  1. Progression-free Survival (PFS)

    PFS was defined as the interval of time from the date of randomization to the earlier of the first documentation of definitive disease progression or death from any cause.

    Time frame: Andecaliximab + mFOLFOX6 median follow-up at the time of the final analysis: 18.64 months; Placebo + mFOLFOX6 median follow-up at the time of the final analysis: 18.74 months

  2. Objective Response Rate (ORR)

    ORR was defined as the percentage of participants who achieve a complete response (CR) or partial response (PR) as assessed by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1. CR was defined as the disappearance of all target lesions and disappearance of all non-target lesions and normalization of tumor marker level. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: Up to 135.4 weeks at the time of final analysis

  3. Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) is any untoward medical occurrence in a clinical study participant administered a medicinal product, which does not necessarily have a causal relationship with the treatment. TEAEs are events in a given study period that meet any of the following criteria: Any AE with onset date of on or after andecalizimab/placebo start date and no later than 30 days after permanent discontinuation of all study treatment (andecaliximab/placebo and chemotherapy) or Any AEs with onset date of on or after the andecaliximab/placebo start date and no later than 55 days after permanent discontinuation of andecaliximab/placebo or AEs leading to discontinuation of andecaliximab/placebo.

    Time frame: First dose date up to the last dose date (maximum:161.7 weeks) plus 30 to 55 days

  4. Percentage of Participants With Clinically Relevant Treatment-emergent Laboratory Abnormalities

    Treatment-emergent laboratory abnormalities were graded per Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03 where 0=None, 1=Mild, 2=Moderate, 3=Severe, 4=Potentially Life Threatening. Treatment-emergent laboratory abnormalities are defined as values that increase at least 1 toxicity grade from baseline at any post-baseline time point, up to 30 days after the last dose of all study treatment, or 55 days after the last dose of andecaliximab/placebo for participants who permanently discontinued all study treatments. If the relevant baseline laboratory value is missing, then any abnormality of at least Grade 1 was considered treatment-emergent.

    Time frame: First dose date up to the last dose date (maximum: 161.7 weeks) plus 30 to 55 days

07

Results

Posted Apr 28, 2020

Participant flow

Participants were enrolled at study sites in Australia, Europe, Chile, Colombia, Peru, Turkey, and the United States. The first participant was screened on 13 October 2015. The last study visit occurred on 15 May 2019.

Participant flow — Overall Study
MilestoneAndecaliximab + mFOLFOX6Placebo + mFOLFOX6
Started218214
Completed00
Not completed218214
Withdrew: Death174168
Withdrew: Unknown reason3032
Withdrew: Withdrew consent911
Withdrew: Investigator's discretion31
Withdrew: Lost to follow-up22

Outcome measures

PrimaryOverall Survival (OS)

OS was defined as the time interval from the date of randomization to death from any cause.

Time frame:
Andecaliximab + mFOLFOX6 median follow-up at the time of final analysis: 19.43 months; Placebo + mFOLFOX6 median follow-up at the time of the final analysis: 19.45 months
Reported as:
Median · months
Overall Survival (OS)
monthsAndecaliximab + mFOLFOX6Placebo + mFOLFOX6
Overall Survival (OS)12.52 (11.2 to 14.0)11.76 (10.3 to 13.5)
Statistical analysis
  • Andecaliximab + mFOLFOX6 vs Placebo + mFOLFOX6 · Log Rank · p = 0.5625 (The significance level at final analysis is 0.046 (two-sided). Stratum with \< 6 participants or no informative event by combined treatment arms was pooled with the smallest adjacent stratum for stratified analyses.) · Cox proportional hazard: 0.93 · 95% CI 0.74 to 1.18Hazard ratio (HR) was stratified by ECOG status, geographic region and primary tumor site with treatment arm as the only covariate.
SecondaryProgression-free Survival (PFS)

PFS was defined as the interval of time from the date of randomization to the earlier of the first documentation of definitive disease progression or death from any cause.

Time frame:
Andecaliximab + mFOLFOX6 median follow-up at the time of the final analysis: 18.64 months; Placebo + mFOLFOX6 median follow-up at the time of the final analysis: 18.74 months
Reported as:
Median · months
Progression-free Survival (PFS)
monthsAndecaliximab + mFOLFOX6Placebo + mFOLFOX6
Progression-free Survival (PFS)7.46 (7.29 to 8.41)7.06 (5.52 to 7.46)
Statistical analysis
  • Andecaliximab + mFOLFOX6 vs Placebo + mFOLFOX6 · Log Rank · p = 0.1031 (The significance level at final analysis was 0.032 (two-sided). Stratum with \< 6 participants or no informative event by combined treatment arms was pooled with the smallest adjacent stratum for stratified analyses.) · Cox proportional hazard: 0.84 · 95% CI 0.67 to 1.04HR was stratified by ECOG status,geographic region;primary tumor site with treatment arm as a covariate.Stratum with \<6 participants or no informative event by combined treatment arms was pooled with smallest adjacent stratum for stratified analyses.
SecondaryObjective Response Rate (ORR)

ORR was defined as the percentage of participants who achieve a complete response (CR) or partial response (PR) as assessed by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1. CR was defined as the disappearance of all target lesions and disappearance of all non-target lesions and normalization of tumor marker level. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
Up to 135.4 weeks at the time of final analysis
Reported as:
Number · percentage of participants
Objective Response Rate (ORR)
percentage of participantsAndecaliximab + mFOLFOX6Placebo + mFOLFOX6
Objective Response Rate (ORR)50.5 (43.6 to 57.3)41.1 (34.5 to 48.0)
Statistical analysis
  • Andecaliximab + mFOLFOX6 vs Placebo + mFOLFOX6 · Cochran-Mantel-Haenszel · p = 0.0493 (The significance level at final analysis was 0.032 (two-sided). Stratum with \< 6 participants or no informative event by combined treatment arms was pooled with the smallest adjacent stratum for stratified analyses.) · Odds ratio (or): 1.47 · 95% CI 1.00 to 2.15OR was stratified by ECOG status, geographic region and primary tumor site. Stratum with \< 6 participants or no informative event by combined treatment arms was pooled with the smallest adjacent stratum for stratified analyses.
  • Andecaliximab + mFOLFOX6 vs Placebo + mFOLFOX6 · Orr difference: 9.4 · 95% CI 0.1 to 18.8The 2-sided 95% confidence interval (CI) of difference for ORR between the treatment and placebo is calculated based on stratum-adjusted Cochran-Mantel-Haenszel proportion.
SecondaryPercentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)

An adverse event (AE) is any untoward medical occurrence in a clinical study participant administered a medicinal product, which does not necessarily have a causal relationship with the treatment. TEAEs are events in a given study period that meet any of the following criteria: Any AE with onset date of on or after andecalizimab/placebo start date and no later than 30 days after permanent discontinuation of all study treatment (andecaliximab/placebo and chemotherapy) or Any AEs with onset date of on or after the andecaliximab/placebo start date and no later than 55 days after permanent discontinuation of andecaliximab/placebo or AEs leading to discontinuation of andecaliximab/placebo.

Time frame:
First dose date up to the last dose date (maximum:161.7 weeks) plus 30 to 55 days
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)
percentage of participantsAndecaliximab + mFOLFOX6Placebo + mFOLFOX6
Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)99.199.5
SecondaryPercentage of Participants With Clinically Relevant Treatment-emergent Laboratory Abnormalities

Treatment-emergent laboratory abnormalities were graded per Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03 where 0=None, 1=Mild, 2=Moderate, 3=Severe, 4=Potentially Life Threatening. Treatment-emergent laboratory abnormalities are defined as values that increase at least 1 toxicity grade from baseline at any post-baseline time point, up to 30 days after the last dose of all study treatment, or 55 days after the last dose of andecaliximab/placebo for participants who permanently discontinued all study treatments. If the relevant baseline laboratory value is missing, then any abnormality of at least Grade 1 was considered treatment-emergent.

Time frame:
First dose date up to the last dose date (maximum: 161.7 weeks) plus 30 to 55 days
Reported as:
Number · percentage of participants
Percentage of Participants With Clinically Relevant Treatment-emergent Laboratory Abnormalities
percentage of participantsAndecaliximab + mFOLFOX6Placebo + mFOLFOX6
Hematology94.489.5
Serum Chemistry91.792.9
Coagulation7.43.3

Adverse events

Collected over All-Cause Mortality: First dose date up to 42 months; Adverse Events: First dose date up to the last dose date (maximum: 161.7 weeks) plus 30 to 55 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Andecaliximab + mFOLFOX6174/218 (79.8%)103/216 (47.7%)209/216 (96.8%)
Placebo + mFOLFOX6168/214 (78.5%)108/210 (51.4%)203/210 (96.7%)
Most frequent serious events
Showing 10 of 165
Most frequent serious events
EventAndecaliximab + mFOLFOX6Placebo + mFOLFOX6
Pulmonary embolismRespiratory, thoracic and mediastinal disorders8/21613/210
VomitingGastrointestinal disorders11/2168/210
Abdominal painGastrointestinal disorders7/2168/210
PneumoniaInfections and infestations7/2165/210
Obstruction gastricGastrointestinal disorders3/2166/210
Febrile neutropeniaBlood and lymphatic system disorders6/2165/210
Gastrointestinal haemorrhageGastrointestinal disorders6/2164/210
DiarrhoeaGastrointestinal disorders3/2165/210
NeutropeniaBlood and lymphatic system disorders4/2164/210
Intestinal obstructionGastrointestinal disorders1/2164/210
Most frequent other events
Showing 10 of 59
Most frequent other events
EventAndecaliximab + mFOLFOX6Placebo + mFOLFOX6
NauseaGastrointestinal disorders106/216118/210
DiarrhoeaGastrointestinal disorders87/21688/210
FatigueGeneral disorders79/21672/210
NeutropeniaBlood and lymphatic system disorders76/21673/210
Decreased appetiteMetabolism and nutrition disorders63/21672/210
Peripheral sensory neuropathyNervous system disorders73/21672/210
AnaemiaBlood and lymphatic system disorders61/21662/210
VomitingGastrointestinal disorders63/21662/210
ConstipationGastrointestinal disorders61/21661/210
AstheniaGeneral disorders62/21652/210

Baseline characteristics

The Intent-to-Treat (ITT) Analysis Set included all randomized participants.

Age, Continuous
Age, Continuous(years)Andecaliximab + mFOLFOX6Placebo + mFOLFOX6Total
Mean60 ± 11.961 ± 11.460 ± 11.7
Sex: Female, Male
Sex: Female, Male(Participants)Andecaliximab + mFOLFOX6Placebo + mFOLFOX6Total
Female5061111
Male168153321
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Andecaliximab + mFOLFOX6Placebo + mFOLFOX6Total
Race — American Indian or Alaska Native011
Race — Asian5510
Race — Black or African American448
Race — White186184370
Race — Not Permitted8614
Race — Other151429
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Andecaliximab + mFOLFOX6Placebo + mFOLFOX6Total
Ethnicity — Hispanic or Latino383270
Ethnicity — Not Hispanic or Latino170173343
Ethnicity — Not Permitted10919
Region of Enrollment
Region of Enrollment(Participants)Andecaliximab + mFOLFOX6Placebo + mFOLFOX6Total
Colombia5611
Romania151328
Hungary111526
United States4759106
Czechia10515
United Kingdom5611
Spain272855
Turkey171835
Belgium235
Poland131124
Italy8614
Australia131831
Chile151126
France10313
Peru448
Germany16824
Type of Cancer
Type of Cancer(Participants)Andecaliximab + mFOLFOX6Placebo + mFOLFOX6Total
Gastric142143285
Gastroesophageal junction7671147
08

Study locations

134 sites
  • Scripps Green Hospital
    La Jolla, California 92037, United States
  • University of Southern California
    Los Angeles, California 90007, United States
  • UCLA Jonsson Comprehensive Cancer Center
    Los Angeles, California 90024, United States
  • Innovative Clinical Research Institute
    Whittier, California 90603, United States
  • Cancer Center of Central Connecticut
    Plainville, Connecticut 06062, United States
  • Omega Research Consultants LLC
    DeBary, Florida 32713, United States
  • Edward Hospital & Health Services
    Naperville, Illinois 60540, United States
  • Parkview Hospital
    Fort Wayne, Indiana 46805, United States
  • Indiana University Goshen Center for Cancer Care
    Goshen, Indiana 46526, United States
  • Ochsner Clinic Foundation
    New Orleans, Louisiana 70816, United States
  • New England Cancer Specialists
    Scarborough, Maine 04074, United States
  • Karamanos Cancer Institute
    Detroit, Michigan 48175, United States
  • HCA Healthcare
    Kansas City, Missouri 64030, United States
  • Carol G. Simon Cancer Center
    Morristown, New Jersey 07901, United States
  • Regional Cancer Care Associates LLC - Sparta
    Sparta, New Jersey 07871, United States
  • Weill Cornell Medical College - New York Presbyterian Hospital
    New York, New York 10065, United States
  • University of Rochester
    Rochester, New York 14627, United States
  • Duke Cancer Institute
    Durham, North Carolina 27710, United States
  • Oncology Hematology Care, Inc.
    Cincinnati, Ohio 45242, United States
  • The Ohio State Medical Center
    Columbus, Ohio 43210, United States
  • Northwest Cancer Specialists
    Portland, Oregon 97213, United States
  • Charleston Hematology Oncology Associates
    Charleston, South Carolina 29403, United States
  • Prairie Lakes Health Care System INC
    Watertown, South Dakota, United States
  • Tennessee Oncology
    Nashville, Tennessee, United States
  • Center for Cancer Blood Disorders
    Fort Worth, Texas, United States
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas, United States
  • Texas Oncology-Seton Williamson
    Round Rock, Texas, United States
  • Scott and White Memorial Hospital
    Temple, Texas, United States
  • Utah Cancer Specialists
    Salt Lake City, Utah, United States
  • Virginia Commonwealth University
    Richmond, Virginia, United States
  • Virginia Mason Seattle Main Clinic
    Seattle, Washington, United States
  • The Canberra Hospital
    Garran, Australian Capital Territory, Australia
  • Chris O'Brien Lifehouse
    Camperdown, New South Wales, Australia
  • The Crown Princess Mary Cancer Centre
    Westmead, New South Wales, Australia
  • Princess Alexandra Hospital
    Brisbane, Queensland, Australia
  • Ashford Cancer Centre
    Kurralta Park, South Australia, Australia
  • Royal Hobart Hospital
    Hobart, Tasmania, Australia
  • Epworth Healthcare
    Richmond, Victoria, Australia
  • Western Health Sunshine Hospital
    St Albans, Victoria, Australia
  • The Tweed Hospital
    Tweed Heads, 2485, Australia
  • Sydney Adventist Hospital
    Wahroonga, Australia
  • Centre Hospitalizer De L'Ardenne
    Libramont, Chevigny, Belgium
  • University Hospital Gent Department of Gastroenterology
    Gent, Belgium
  • Instituto Nacional Del Cancer
    Santiago, Chile
  • Instituto Clinico Oncologico del Sur
    Temuco, Chile
  • Hospital Clinico Vina Del Mar
    Vina del Mar, Chile
  • Oncomedica S.A
    Monteria, Cordoba, Colombia
  • Dundacion Oftalmologica de Santander Clinica Ardila Lulle La Foscal
    Floridablanca, Colombia
  • Hospital Pablo Tobon Uribe
    Medellin, Colombia
  • Centro Medico Imbanaco de Cali S.A
    Valle, Colombia
  • Fakultni Nemocnice Brno
    Brno, Czechia
  • Fakultni nemocnice Hradec Kralove
    Hradec Kralove, Czechia
  • University Hospital - Czech
    Olomouc, Czechia
  • Thomayer Hospital
    Prague 4, Czechia
  • Oblastni Nemocnice Pribram
    Pribram, Czechia
  • CHU Jean Minjoz
    Besancon, France
  • CHRU de Brest, Hopital Morvan, Institut de Cancerologie et d'Hematologie
    Brest Cedex, France
  • Hôpitaux Civils de Colmar
    Colmar, France
  • Institut Paoli Calmettes
    Marseille Cedex 9, France
  • CHU de Nice-l Archet
    Nice Cedex 3, France
  • CH Annecy-Gennevois
    Pringy Cedex, France
  • Kliniken Nordoberpfalz AG
    Weiden, Bavaria, Germany
  • Klinikum rechts der Isar Technical University of Ismaninger
    Munich, Bayern, Germany
  • DRK Klinken Berlin Abteilungsleiter Chiurgische Okologie
    Berlin, Germany
  • Universitätsklinikum Carl Gustav Carus
    Dresden, Germany
  • Kliniken Essen Mitte Studiensekretariat Onkologie Evang. Huyssens-Stiftung
    Essen, Germany
  • Krankenhaus Nordwest gGmbH Institut für Klinisch Onkologische Med Klinik II
    Frankfurt, Germany
  • Cancer Center Heilbronn-Franken, SLK-Kliniken
    Heilbronn, Germany
  • Staedtisches Klinikum Muenchen Bogenhausen
    Muenchen, Germany
  • Zentrum fur Innere Medizin Stauferklinikum Schwab
    Mutlangen, Germany
  • Universitatsklinikum Ulm
    Ulm, Germany
  • Egyesített Szent István és Szent László Kórház -Rendelőintézet
    Budapest, Hungary
  • Debreceni Egyetem Klinikai Központ
    Debrecen, Hungary
  • Human Klinikai Vizsgalatok Regisztracios Kozpont - HKVRK
    Gyor, Hungary
  • Pandy Kalman Hospital
    Gyula, Hungary
  • Borsod County Hospital Clinical Oncological and Radiotheraputic Center
    Miskolc, Hungary
  • Zala Megyei Korhaz Pozva Diabetes Kulsokorhaz
    Zalaegerszeg, Hungary
  • University Hospital Company of Pisana
    Pisa, PI, Italy
  • Ente Ospedaliero Ospedali Galliera
    Genova, Italy
  • IRCCS A.O.U. San Martino
    Genova, Italy
  • Fondazione IRCCS Istituto Nazionale dei Tumori
    Milano, Italy
  • Ospedale San Raffaele
    Milano, Italy
  • S.C. Oncologia Medica Azienda Ospedaliera Valtellina e Valchiavenna Presidio Ospedaliero di Sondrio
    Sondrio, Italy
  • Azienda Ospedaliera Treviglio Caravaggio U.O. Oncologia Medica
    Treviglio, Italy
  • Centro de Investigacion Instituto de oncologia y Radiotherpia de la Clinica
    San Isidro, Lima, Peru
  • Centro Medico monte Carmelo
    Arequipa, Peru
  • Clinica Anglo Americana Calle Alfredo Salazar
    San Isidro, Peru
  • Beskidzkie Oncology Center
    Bielsko-Biala, Poland
  • Wojewodzki Szpital Zespolony w Elblagu Oddzial Onkologiczny
    Elblag, Poland
  • Wielkopolskie Centrum Onkologii
    Poznan, Poland
  • Mrukmed Lekarz Beata Madej Mruk i Partner Spolka Partnerska Oddzial Nr 1 w Rzeszowie
    Rzeszow, Poland
  • Wojewodzki Szpital Zespolony im L Rydygiera w Toruniu
    Torun, Poland
  • Wojskowy Instytut Medyczny
    Warsaw, Poland
  • Klinka Gastroenterologii Okologicznej Centrum Okologii Instytut
    Warszawa, Poland
  • Medisprof srl Oncologie P TA
    Cluj-Napoca, Judet Cluj, Romania
  • Fundeni Clinical Institute
    Bucuresti, Romania
  • GRAL Medical SRL
    Bucuresti, Romania
  • Centrul de Oncologie Sfantul Nectarie SRL, Oncologie
    Craiova, Romania
  • Sc Oncolab Srl
    Craiova, Romania
  • SC Centrul de Oncologie Euroclinic SRL, Oncologie
    Iaşi, Romania

Showing the first 100 of 134 sites across 16 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Shah MA, Bodoky G, Starodub A, Cunningham D, Yip D, Wainberg ZA, Bendell J, Thai D, He J, Bhargava P, Ajani JA. Phase III Study to Evaluate Efficacy and Safety of Andecaliximab With mFOLFOX6 as First-Line Treatment in Patients With Advanced Gastric or GEJ Adenocarcinoma (GAMMA-1). J Clin Oncol. 2021 Mar 20;39(9):990-1000. doi: 10.1200/JCO.20.02755. Epub 2021 Feb 12. PubMed 33577358 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2015 to primary completion in May 2019, 43 months.

Results were first posted in Apr 2020, 11 months after primary completion.

Of 45 industry-sponsored phase 3 interventional studies under Stomach Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 55. This study's 43 months is close to that.

Counting every sponsor, half of 118 studies reached it within 52 months; a quarter within 39 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2015
First posted
Sep 10, 2015
StartActual
Oct 13, 2015
Primary completionActual
May 15, 2019
CompletionActual
May 15, 2019
Results first posted
Apr 28, 2020
Last update
May 26, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 26, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02545504
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Sep 10, 2015
Start date
Oct 13, 2015
Primary completion
May 15, 2019
Completion
May 15, 2019
Results posted
Apr 28, 2020
Last update
May 26, 2020

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Andecaliximab

Start the discussion